IONS Ionis Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IONS

Price (delayed)

$49.41

Market cap

$7.09B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.87

Enterprise value

$8.19B

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and ...

Highlights
The company's debt rose by 16% YoY but it fell by 2.5% QoQ
The company's equity fell by 47% YoY and by 26% QoQ
The net income has declined by 32% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.ionispharma.com/
Peers: NRC NWBO

Key stats

What are the main financial stats of IONS
Market
Shares outstanding
143.47M
Market cap
$7.09B
Enterprise value
$8.19B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
22.45
Price to sales (P/S)
11.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.32
Earnings
Revenue
$615.03M
EBIT
-$314.75M
EBITDA
-$289.03M
Free cash flow
-$315.25M
Per share
EPS
-$2.87
Free cash flow per share
-$2.2
Book value per share
$2.2
Revenue per share
$4.29
TBVPS
$20.47
Balance sheet
Total assets
$2.93B
Total liabilities
$2.62B
Debt
$1.45B
Equity
$315.46M
Working capital
$2.18B
Liquidity
Debt to equity
4.6
Current ratio
6.39
Quick ratio
5.88
Net debt/EBITDA
-3.81
Margins
EBITDA margin
-47%
Gross margin
98.4%
Net margin
-66.6%
Operating margin
-90.3%
Efficiency
Return on assets
-14.5%
Return on equity
-90.8%
Return on invested capital
-8.8%
Return on capital employed
-12.4%
Return on sales
-51.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IONS stock price

How has the Ionis Pharmaceuticals stock price performed over time
Intraday
2.21%
1 week
-0.34%
1 month
12.17%
1 year
27.48%
YTD
30.82%
QTD
8.93%

Financial performance

How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$615.03M
Gross profit
$605.27M
Operating income
-$555.63M
Net income
-$409.45M
Gross margin
98.4%
Net margin
-66.6%
The company's net margin fell by 36% QoQ
The net income has declined by 32% since the previous quarter
The gross profit is down by 30% year-on-year and by 2.6% since the previous quarter
IONS's revenue is down by 30% YoY and by 2.5% QoQ

Growth

What is Ionis Pharmaceuticals's growth rate over time

Valuation

What is Ionis Pharmaceuticals stock price valuation
IONS P/E details
P/E
N/A
P/B
22.45
P/S
11.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.32
Ionis Pharmaceuticals's EPS has decreased by 32% QoQ
The stock's price to book (P/B) is 155% more than its 5-year quarterly average of 8.8 and 66% more than its last 4 quarters average of 13.5
The company's equity fell by 47% YoY and by 26% QoQ
The P/S is 31% more than the 5-year quarterly average of 8.8 and 21% more than the last 4 quarters average of 9.5
IONS's revenue is down by 30% YoY and by 2.5% QoQ

Efficiency

How efficient is Ionis Pharmaceuticals business performance
IONS's return on equity has dropped by 53% since the previous quarter
Ionis Pharmaceuticals's return on sales has decreased by 34% QoQ
IONS's return on assets is down by 27% since the previous quarter
Ionis Pharmaceuticals's ROIC has decreased by 26% from the previous quarter

Dividends

What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IONS.

Financial health

How did Ionis Pharmaceuticals financials performed over time
The total assets is 12% greater than the total liabilities
The total liabilities is up by 43% year-on-year and by 3% since the previous quarter
IONS's quick ratio is down by 30% since the previous quarter and by 16% year-on-year
Ionis Pharmaceuticals's debt to equity has soared by 118% YoY and by 32% from the previous quarter
The company's equity fell by 47% YoY and by 26% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.